Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
May 11, 2022 16:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment...
Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates
May 09, 2022 16:05 ET
|
Caribou Biosciences, Inc.
-- Initial ANTLER Phase 1 clinical data scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010, the Company’s lead allogeneic cell therapy candidate, in...
Caribou Biosciences to Present at Upcoming Investor Conference
May 03, 2022 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
May 02, 2022 16:30 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the...
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress
April 25, 2022 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the...
Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting
April 08, 2022 13:07 ET
|
Caribou Biosciences, Inc.
-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- -- Data support an expected...
Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 21, 2022 16:02 ET
|
Caribou Biosciences, Inc.
-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL -- -- 2022 submission...
Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 08, 2022 20:19 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...
Caribou Biosciences to Present at Upcoming Investor Conferences
March 07, 2022 16:11 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...
Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 07, 2022 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel...